Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy

被引：2
|
作者：
Kyvsgaard, Emil R. [1 ,2 ,3 ]
Riley, Caroline [1 ,2 ]
Clausen, Michael Roost [4 ]
Harslof, Mads [1 ,2 ]
Heftdal, Line Dam [5 ]
Niemann, Carsten U. [1 ]
Gronbaek, Kirsten [1 ,2 ]
Hutchings, Martin [1 ,2 ]
Husby, Simon [1 ,2 ,3 ,6 ]
机构：
[1] Rigshosp, Dept Hematol, Copenhagen, Denmark
[2] Rigshosp, Phase 1 Unit, Copenhagen, Denmark
[3] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark
[4] Vejle Univ Hosp, Dept Hematol, Vejle, Denmark
[5] Rigshosp, Copenhagen Univ Hosp, Viroimmunol Res Unit, Dept Infect Dis, Copenhagen, Denmark
[6] Rigshosp, Dept Hematol, Gronbaek Grp, Ole Maaloes Vej 5, bygning 2, 3 Sal, DK-2200 Copenhagen N, Denmark
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 01期
关键词：
D O I：
10.1111/bjh.19156
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：356 / 360
页数：5
相关论文
共 50 条
  • [21] Bi20 a new trifunctional bispecific antibody (CD20xCD3) in the treatment of resistant B cell tumors: First clinical data.
    Simoes, BP
    Stanglmaier, M
    Faltin, M
    Ruf, P
    Schmid, C
    Bergmann, M
    Humann, M
    Wegner, H
    Lang, N
    Ledderose, G
    Lindhofer, H
    Kolb, HJ
    BLOOD, 2003, 102 (11) : 297B - 297B
  • [22] Activation of T- and NK-Cells through CD19xCD3 and CD19xCD16A Bispecific TandAb Antibodies in Patients with B-Cell Non-Hodgkin's Lymphoma
    Poertner, L. M.
    Uhrberg, M.
    Schoenberg, K.
    Bruennert, D.
    Reusch, U.
    Little, M.
    Haas, R.
    Neumann, F.
    MEDIZINISCHE KLINIK, 2010, 105 (03) : 213 - 213
  • [23] Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy
    Susan C. Irvin
    Amanda D’Orvilliers
    Nicolin Bloch
    Kayla Boccio
    Jason Pennucci
    Jurriaan Brouwer-Visser
    Erica Ullman
    Manoj Rajadhyaksha
    Mohamed Hassanein
    Terra Potocky
    Albert Torri
    Aynur Hermann
    Michael A. Partridge
    The AAPS Journal, 24
  • [24] Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy
    Irvin, Susan C.
    D'Orvilliers, Amanda
    Bloch, Nicolin
    Boccio, Kayla
    Pennucci, Jason
    Brouwer-Visser, Jurriaan
    Ullman, Erica
    Rajadhyaksha, Manoj
    Hassanein, Mohamed
    Potocky, Terra
    Torri, Albert
    Hermann, Aynur
    Partridge, Michael A.
    AAPS JOURNAL, 2022, 24 (04):
  • [25] Treatment of low grade B-cell lymphoma with bispecific CD3XCD19 antibodies and monospecific bivalent CD28 antibodies. Preclinical and clinical data
    Manzke, O
    Tesch, H
    Engert, A
    Diehl, V
    Bohlen, H
    BLOOD, 1996, 88 (10) : 342 - 342
  • [26] B-Cell Lymphoma Associated with COVID-19 Infection: A Case Report
    Yang, Lili
    He, Jiawei
    Lin, Xiaoji
    Zhao, Dandan
    Lin, Xianhui
    Yan, Zhihan
    Chen, Feng
    CURRENT MEDICAL IMAGING, 2022, 18 (11) : 1231 - 1234
  • [27] Activation of T- and NK- Cells through CD19xCD3 and CD19xCD16A Bispecific TandAb Antibodies in Patients with B-Cell Non-Hodgkin's Lymphoma.
    Poertner, Lisa
    Uhrberg, Markus
    Schoenberg, Kathrin
    Bruennert, Daniela
    Reusch, Uwe
    Little, Melvin
    Haas, Rainer
    Neumann, Frank
    BLOOD, 2009, 114 (22) : 773 - 773
  • [28] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
    Bannerji, Rajat
    Arnason, Jon E.
    Advani, Ranjana H.
    Brown, Jennifer R.
    Allan, John N.
    Ansell, Stephen M.
    Barnes, Jeffrey A.
    O'Brien, Susan M.
    Chavez, Julio C.
    Duell, Johannes
    Rosenwald, Andreas
    Crombie, Jennifer L.
    Ufkin, Melanie
    Li, Jingjin
    Zhu, Min
    Ambati, Srikanth R.
    Chaudhry, Aafia
    Lowy, Israel
    Topp, Max S.
    LANCET HAEMATOLOGY, 2022, 9 (05): : E327 - E339
  • [29] Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma
    Kyvsgaard, Emil Ramso
    Clausen, Michael Roost
    Riley, Anna Caroline Hasselbalch
    Niemann, Carsten Utoft
    Sjo, Lene
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    BLOOD, 2023, 142
  • [30] Immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CART cell therapy
    Iraguha, Thierry
    Dahiya, Saurabh
    Avila, Stephanie
    Rapoport, Aaron
    Luetkens, Tim
    Atanackovic, Djordje
    CANCER RESEARCH, 2022, 82 (12)
12345